Engineered immune cells take on deadly brain tumors
NCT ID NCT03170141
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment for glioblastoma, an aggressive brain cancer. The approach uses a patient's own immune cells, modified in the lab to better recognize and attack the tumor, combined with chemotherapy. The main goal is to check the safety of this therapy in 30 people with recurrent brain cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Brain cancer vaccine targets survivin protein to boost immune attack
- Mapping the hidden toll of brain radiation on young minds
- Could an ALS drug clear the fog of chemo brain?
- Electric field device tested for Hard-to-Treat brain tumor
- Engineered immune cells target deadly brain tumors in children